Observational studyScientific reports2025
Tolerance and effectiveness of inhaled antibiotics at standard or low doses in COPD patients with chronic Pseudomonas aeruginosa bronchial infection.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the tolerance and effectiveness of standard doses (StD) and low doses (LoD) of inhaled antibiotics (IA), in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). Single-center, observational, retrospective, follow-up study of patients with COPD and CBI by PA treated with IA between 2012 and 2021. One year before and one after the first IA dose were analysed. 87 patients were included (86 men) with a mean FEV1(%) of 46.3%. Intolerance to IA was observed in 54 (62.1%), with a median time of 30 days (IQR: 15, 90). Only a higher FEV1(%) was associated with lower probability of intolerance (hazard ratio: 0.98, 95% confidence interval 0.97 to 0.99; p = 0.021). Seven of 15 (46.6%) patients who did not tolerate StD tolerated LoD. Those unable to tolerate LoD also had worse FEV1(%) (38.4% (SD:18.7%) versus 48.1% (SD: 16.4%); p = 0.018). Treatments lasting 6-12 months improved symptoms and reduced PA isolations (- 2.1; P < 0.001) and exacerbations (-1.7, P < 0.001). In 19 patients LoD treatment reduced exacerbations (-2.1, P = 0.003), days of hospitalization (-7.4, P = 0.036) and PA isolations (-2, P = 0.001) with clinical improvement. Antimicrobial resistance was not observed in any case receiving LoD of IA. More than half of our COPD patients treated with IA for CBI by PA presented respiratory intolerance during the first three months related to greater severity of airway obstruction. Treatment with LoD of IA appears to be an effective and safe alternative for some patients unable to tolerate StD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.